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Localization and Production of Angiotensin II in the
Isolated Perfused Rat Heart
Larissa M. de Lannoy, A.H. Jan Danser, Angelique M.B. Bouhuizen,
Pramod R. Saxena, Maarten A.D.H. Schalekamp
Abstract—We used a modification of the isolated perfused rat heart, in which coronary effluent and interstitial transudate
were separately collected, to investigate the localization and production of angiotensin II (Ang II) in the heart. During
combined renin (0.7 to 1.5 pmol Ang I/mL per minute) and angiotensinogen (6 to 12 pmol/mL) perfusion (4 to 8
mL/min) for 60 minutes (n53), the steady-state levels of Ang II in interstitial transudate in two consecutive 10-minute
periods were 4.361.5 and 3.661.5 fmol/mL compared with 1.160.4 and 1.160.6 fmol/mL in coronary effluent
(mean6half range). During perfusion with Ang II (n55), steady-state Ang II in interstitial transudate was 32619% of
arterial Ang II compared with 65616% in coronary effluent (mean6SD, P,.02). During perfusion with Ang I (n55),
Ang II in interstitial transudate was 5.160.6% of arterial Ang I compared with 2.260.3% in coronary effluent (P,.05).
The tissue concentration of Ang II in the combined renin/angiotensinogen perfusions (per gram) was as high as the
concentration in interstitial transudate (per milliliter). Addition of losartan (1026 mol/L) to the renin/angiotensinogen
perfusion (n53) had no significant effect on the tissue level of Ang II, whereas losartan in the perfusions with Ang I
(n55) or Ang II (n55) decreased tissue Ang II to undetectably low levels. The results indicate that the heart is capable
of producing Ang II and that this can lead to higher levels in tissue than in blood plasma. Cardiac Ang II does not appear
to be restricted to the extracellular fluid. This is in part due to AT1-receptor–mediated cellular uptake of extracellular
Ang II, but our results also raise the possibility of intracellular Ang II production. (Hypertension. 1998;31:1111-1117.)
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Angiotensin II is the primary mediator of the physiolog-ical actions of the RAS and has an important function in
cardiovascular homeostasis. Ang II in the circulation is
produced by the conversion of Ang I by ACE of the vascular
endothelium. Ang I is generated in the circulation by the
action of renin from the kidney on its substrate, angioten-
sinogen, produced by the liver. The various RAS components
have all been identified in tissues,1–4 which suggests the
existence of a locally acting RAS in the tissues, apart from the
RAS in the circulation.
Local Ang II production in the heart is often invoked to
explain the results of heart failure trials evaluating the effects of
drugs that block angiotensin formation.5,6 Knowledge of cardiac
Ang I and II production, however, is still fragmentary and little
is known about its regulation and physiological significance.3
In a previous study we used a modified Langendorff rat
heart preparation to investigate the production of Ang I in
cardiac tissue.7 This isolated heart preparation enabled us to
collect IST separately from the CE. During perfusion with
renin and angiotensinogen, Ang I appeared in the transudate.
This Ang I was produced in cardiac tissue and was not
derived from Ang I in the perfusate. There was no indication
that the heart was capable of producing Ang I independent of
arterially delivered renin and angiotensinogen. Observations
in nephrectomized pigs also indicated that the cardiac tissue
levels of Ang I and II are determined by kidney-derived
renin.4
Here we report on a study in which we used the same
modified Langendorff rat heart preparation to investigate the
production of Ang II. The presence of Ang II in tissue
depends on arterial delivery of this peptide and on its local
generation. Ang II may be formed from arterially delivered
Ang I or from in situ synthesized Ang I. Extracellular Ang II
is known to be taken up into cells by AT1-receptor endocy-
tosis.8–11 The adrenals, the kidneys, and the heart accumulate
Ang II from the circulation by an AT1-receptor–mediated
process, probably endocytosis.12
The questions addressed by the present study are: In which
tissue compartments is Ang II localized in the heart, where is
it produced, and how are its levels in cardiac tissue influenced
by AT1-receptor–mediated cellular uptake?
Methods
Chemicals and Reagents
[Ile5]-Ang-(1–10) decapeptide (Ang I) and [Ile5]-Ang-(1–8) octapep-
tide (Ang II) were obtained from Bachem. BSA was from Sigma,
Received August 19, 1997; first decision September 11, 1997; revision accepted December 15, 1997.
From the Departments of Internal Medicine I (L.M. de L., A.M.B.B., M.A.D.H.S.) and Pharmacology (L.M. de L., A.H.J.D., P.R.S.), Erasmus
University Rotterdam, The Netherlands.
Correspondence to A.H. Jan Danser, PhD, Department of Pharmacology, Room EE 1418b, Erasmus University, Dr Molewaterplein 50, 3015 GE
Rotterdam, Netherlands.
© 1998 American Heart Association, Inc.
1111
1,10-phenanthroline was from Merck, and sodium pentobarbital was
obtained from Apharma. The AT1-receptor antagonist losartan was a
kind gift of Dr R.D. Smith, Du Pont Merck, Wilmington, Del. The
renin inhibitor remikiren was a kind gift of Dr P. van Brummelen,
Hoffmann-La Roche, Basel, Switzerland. Renin was prepared from
porcine kidneys as described before.7 Angiotensinogen was prepared
from plasma of nephrectomized pigs.7 All other reagents were of
standard laboratory grade.
Preparation of the Modified Langendorff Heart
All experiments were performed under the regulation of the Animal
Care Committee of the Erasmus University, Rotterdam, The Neth-
erlands, in accordance with the “Guiding principles in the care and
use of animals” as approved by the American Physiological Society.
Male Wistar rats (Harlan, Zeist, The Netherlands; 280 to 400 g)
were anesthetized with pentobarbital (60 mg/kg IP) and heparinized
(5000 U/kg IV). The hearts (1.0 to 1.4 g) were rapidly excised,
cooled in ice-cold Tyrode’s buffer (125 mmol/L NaCl, 4.7 mmol/L
KCl, 1.4 mmol/L CaCl2, 20 mmol/L NaHCO3, 0.4 mmol/L NaH2PO4,
1.0 mmol/L MgCl2, 10 mmol/L D-glucose, pH 7.4) until contractions
stopped, and prepared for Langendorff perfusion. Carbogen-gassed
(95% O2/5% CO2) Tyrode’s buffer at 37°C was continuously
perfused immediately after cannulation of the aorta at a constant
perfusion pressure of 80 mm Hg. Subsequently the pulmonary artery
was cannulated and the caval and pulmonary veins were carefully
ligated. After the ligation procedure, which took 30 to 45 minutes,
the hearts were allowed to stabilize for 30 minutes.
With this modified Langendorff heart preparation it is possible to
collect separately CE and IST.7,13 CE, ejected by the right ventricle, was
collected through the cannulated pulmonary artery. IST, which drips
from the heart, was collected at the apex. IST flow was 0.03 to 0.16
mL/min, corresponding with 0.7% to 2% of the coronary flow. An IST
flow .2% of the coronary flow, which occurred in one out of four to
five heart preparations, was considered to be an indication of leakage,
for example, from veins that were not properly ligated.7 Hearts with such
high IST flow were therefore not used. IST is derived from the ISF, and
the Ang I and II concentrations in IST are considered to be representa-
tive for the Ang I and II concentrations in ISF.7
Perfusions With RAS Components and Collection
of CE and IST
The Langendorff hearts were perfused with Tyrode’s buffer through
the cannulated aorta. After a 30-minute stabilization period, RAS
components were infused through a T-connection into the cannulated
aorta.
CE and IST were collected during and after the infusions.
One-minute (4 to 8 mL), 4-minute (16 to 40 mL), or 10-minute
samples (40 to 80 mL) of CE were collected into BSA-coated 10- or
50-mL polystyrene tubes. Individual drops of IST ('50 mL each
minute) and 4-minute ('200 mL) or 9- to 10-minute ('500 mL)
samples of IST were collected into BSA-coated 1.5-mL Eppendorf
cups. The Eppendorf cups and polystyrene tubes contained a mixture
of inhibitors, 5, 10, or 25 mL in the Eppendorf cups (for the
individual drops of IST and the 4-minute and 10-minute IST
samples, respectively), and 250, 2500, and 5000 mL in the polysty-
rene tubes (for the 1-minute, 4-minute, and 10-minute CE samples),
to prevent the ongoing formation of Ang I, the conversion of Ang I
to Ang II, and the degradation of Ang I and II. The mixture consisted
of 0.2 mmol/L of the renin inhibitor remikiren, 125 mmol/L
disodium EDTA, and 25 mmol/L 1,10-phenanthroline.7 Remikiren is
an inhibitor of human renin (IC50 7310210 mol/L). It also inhibits
porcine renin (IC50 531028 mol/L).4
The Eppendorf cups and polystyrene tubes were kept on ice during
the perfusions so that the samples were rapidly cooled during their
collection and remained cold (0° to 4°C) during the experiment.
After the experiment was finished, the samples for Ang I and II
measurements were frozen at 280°C.
Perfusion With Ang II to Study the Localization of
Arterially Delivered Ang II
Langendorff hearts were perfused for 15 minutes with Ang II. Ang
II diluted with Tyrode’s buffer to a concentration of 400 pmol/mL
was infused into the perfusion system at a rate of 0.1 mL/min. Ang
II caused a transient fall in coronary flow that stabilized in 2 to 3
minutes at 4 to 9 mL/min. After the Ang II infusion had been
switched off, the heart was either quickly removed from the
perfusion apparatus and transferred into liquid nitrogen or subjected
to a 10-minute washout period. The tissue was frozen within 45
seconds after the Ang II infusion had been stopped. One-minute
samples of CE and individual drops of IST were collected during the
infusion and washout periods in order to study the uptake and
washout kinetics of Ang II. A steady state was reached within 5
minutes. Samples of CE and IST that had been collected from 7 to 10
minutes and from 11 to 14 minutes were used to determine the
steady-state levels of Ang II. The frozen hearts that were not
subjected to a washout period were used to measure the steady-state
tissue levels of Ang II.
In a separate series of experiments, the steady-state levels of Ang
II in CE, IST, and cardiac tissue were measured during perfusions
with Ang II in the presence of the AT1-receptor antagonist losartan
(1026 mol/L) in the perfusion fluid. Coronary flow in these experi-
ments was 4 to 11 mL/min.
Perfusion With Ang I to Study the Localization
of Arterially Delivered Ang I and Locally
Generated Ang II
Langendorff hearts were perfused for 15 minutes with Ang I. Ang I
diluted with Tyrode’s buffer to a concentration of 400 pmol/mL was
infused into the perfusion system at a rate of 0.1 mL/min. Coronary
flow in these experiments was 5 to 10 mL/min. The uptake and
washout kinetics of Ang I are known from our previous study.7 After
the Ang I infusion had been switched off, the heart was removed
from the perfusion apparatus and immediately transferred into liquid
nitrogen. Samples of CE and IST collected from 7 to 10 minutes and
from 11 to 14 minutes were used to determine the steady-state levels
of Ang I and II. The frozen hearts were used to measure the
steady-state tissue levels of Ang I and II.
In a separate series of experiments, the steady-state levels of Ang
I and II in CE, IST, and cardiac tissue were measured during
perfusions with Ang I in the presence of the AT1-receptor antagonist
losartan (1026 mol/L) in the perfusion fluid. Coronary flow in these
experiments was 4 to 9 mL/min.
Perfusions With Renin Combined With
Angiotensinogen to Study the Localization of
Locally Generated Ang I and II
Langendorff hearts were perfused for 60 minutes with renin and
angiotensinogen. Porcine renin diluted with Tyrode’s buffer to a
concentration of '60 pmol Ang I/min per milliliter and undiluted
porcine angiotensinogen (500 pmol/mL) were infused into the
perfusion system both at a rate of 0.1 mL/min. Coronary flow was 4
to 8 mL/min. The final concentrations of renin and angiotensinogen
in the perfusion fluid ranged from 0.7 to 1.5 pmol Ang I/mL per
minute and from 6 to 12 pmol/mL, respectively. These experiments
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were performed in the presence or absence of the AT1-receptor
antagonist losartan (1026 mol/L) in the perfusion fluid. The renin and
angiotensinogen solutions were kept at 4°C until they reached the
aorta, in order to prevent angiotensin generation outside the heart.7
After the perfusion had been switched off, the hearts were frozen in
liquid nitrogen.
Samples of CE and IST collected from 31 to 40 minutes and from
46 to 55 minutes were used to determine the steady-state levels of
Ang I and II. Collections from 41 to 45 and from 56 to 60 minutes
had been used for other measurements, reported in our previous
study.7 The frozen hearts were used to measure the steady-state tissue
levels of Ang I and II.
Measurements of Ang I and II
All angiotensin measurements were performed by a technician who
did not know which experiments had been carried out with losartan
and which without this drug. The Ang I and II concentrations in CE
and IST samples, collected during Ang I and II perfusions, were
measured directly with sensitive radioimmunoassays.14,15 Measure-
ments were made in 50 mL of undiluted CE and in 50 mL IST diluted
with 25 mL of 0.25 mol/L phosphate buffer, pH 7.4, containing 0.15
mol/L NaCl. The lowest measurable Ang I concentration was 15
fmol/mL in CE and 40 fmol/mL in IST. The lowest measurable Ang
II concentration was 10 fmol/mL in CE and 25 fmol/mL in IST.
The Ang I and II concentration of CE and IST samples obtained
during infusion with renin combined with angiotensinogen, as well
as the cardiac tissue concentrations of Ang I and II both during Ang
I and II perfusion and during combined renin and angiotensinogen
perfusion, were measured by radioimmunoassay after SepPak ex-
traction and reversed-phase HPLC separation.4,14,15 To measure tissue
Ang I and II, the frozen hearts were minced and homogenized (1:10,
wt/vol) in an iced solution of 0.1 mol/L HCl/80% ethanol. Homog-
enates were centrifuged at 20 000g for 25 minutes at 4°C. Ethanol in
the supernatant was evaporated under constant air flow. The remain-
der of the supernatant was diluted in 20 mL 1% ortho-phosphoric
acid and centrifuged again at 20 000g. The supernatant was diluted
with 1% ortho-phosphoric acid 1:1 (vol/vol). The tissue homogenate
supernatants and CE and IST samples were concentrated over
SepPak columns (SepPak C18, Waters), and the concentrated ex-
tracts were subjected to HPLC followed by radioimmunoassay.
125I-labeled Ang I had been added as an internal standard to the CE
and IST samples before SepPak extraction and to tissue before its
homogenization. Recovery was better than 70%, and the Ang I and
II results were corrected for incomplete recovery. The lowest level of
Ang I that could be measured with the Ang I radioimmunoassay after
HPLC separation was 2.0 fmol/g in cardiac tissue, 0.05 fmol/mL in
CE, and 2.5 fmol/mL in IST. The lowest level of Ang II that could
be measured with the Ang II radioimmunoassay after HPLC sepa-
ration was 1.0 fmol/g in cardiac tissue, 0.05 fmol/mL in CE, and 1.5
fmol/mL in IST.
Calculations
To determine in which tissue compartments Ang I and II are
localized in the heart, the measured tissue levels of Ang I and II were
compared with the levels predicted on the basis of the presence of
these peptides in the cardiac extracellular fluid compartments. If the
measured tissue levels are higher than predicted, angiotensin is not
restricted to the extracellular fluid compartments. If the measured
tissue levels are lower than predicted, angiotensin has disappeared
from the extracellular fluid compartments during the period between
the moment the heart has been removed from the perfusion equip-
ment and the moment the tissue is transferred into liquid nitrogen.
The predicted tissue level (fmol/g) was calculated as follows:
Predicted tissue Ang concentration
5[AngIST]3ISF volume1[AngCE]3IVF volume
in which [AngIST] is the steady-state Ang I or II concentration in IST
and [AngCE] is the steady-state Ang I or II concentration in CE. ISF
volume is the cardiac interstitial fluid volume (0.23 mL/g), deter-
mined previously as the difference between the distribution volume
of 51Cr-EDTA and 125I-HSA,7 and IVF volume is the intravascular
fluid volume (0.38 mL/g), determined previously as the distribution
volume of 125I-HSA.7 In this calculation, it is assumed that [AngCE] is
representative for the angiotensin concentration in most of the
intravascular fluid compartment (coronary venules and veins and
right ventricle).
Statistical Analysis
The Ang I and II levels in CE, IST, and cardiac tissue during Ang I
or II perfusion are expressed as a percentage of the arterial levels of
Ang I (Ang I perfusion) or Ang II (Ang II perfusion). Ang I and II
levels in CE, IST, and cardiac tissue during renin combined with
angiotensinogen perfusion are given as absolute values. Differences
between the experimental groups were evaluated for statistical
significance by Student’s unpaired t test. Differences within groups
were evaluated for statistical significance by Student’s paired t test.
Bonferroni’s correction was applied to adjust for multiple compari-
sons. Differences were assigned to be significant for values of
P,.05.
Results
Localization of Arterially Delivered Ang II During
Perfusion With Ang II
During perfusion with Ang II (n510), the steady-state Ang II
level in CE was 65% of the arterial level (Fig 1 and Fig 2).
Figure 1. Ang II concentration in IST (F) and CE (E) during and
after perfusion with Ang II (n55). Data (mean6SEM) are pre-
sented as a percentage of the arterial Ang II concentration.
Figure 2. Steady-state Ang II concentration in CE and IST dur-
ing perfusion with Ang II for 15 minutes and the Ang II concen-
tration in cardiac tissue shortly after the perfusion. Perfusions
were carried out in the absence (n55) or presence (n55) of lo-
sartan (1026 mol/L). The mean of the levels of the 7- to
10-minute and 11- to 14-minute perfusion periods was taken as
the steady-state concentration. Data (mean6SD) are presented
as a percentage of the arterial Ang II concentration. Ang II in IST
was lower than in CE (P,.02) and higher than in cardiac tissue
(P,.05) both with and without losartan. n.d. indicates not
detectable.
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Thus 35% of the arterially delivered Ang II was removed by
the heart during a single passage of the perfusate. The
intravascular fluid volume of the Langendorff heart was
measured in our previous study of this model and was found
to be 0.38 mL/g. Heart weight was 1.0 to 1.4 g, thus the
intravascular fluid volume per heart was 0.38 to 0.53 mL. The
perfusate flow was 4 to 9 mL/min; therefore the perfusate
transit time of the isolated heart preparation was 0.04 to 0.13
minutes. It can be concluded, therefore, that 35% of the
arterially delivered Ang II was removed in 0.04 to 0.13
minutes, which corresponds with a t1⁄2 of 0.06 to 0.21 minute.
A steady-state level in IST was reached within 5 minutes. It
was '35% of the arterial level (39% in the experiments in
which also the Ang II washout was measured, Fig 1; 32% in
the experiments in which also the tissue Ang II concentration
was measured, Fig 2). The steady-state Ang II concentration
in IST was significantly lower than in CE.
After discontinuation of the Ang II perfusion, Ang II
disappeared from IST, in a monophasic way, with a t1⁄2 of
1.460.3 minutes (mean6SD, n55).
The cardiac tissue level of Ang II (per gram of tissue),
shortly after the Ang II perfusion had been switched off, was
'5% of the arterial level (per milliliter of perfusate) (Fig 2).
This is lower than predicted on the basis of the presence of
Ang II the cardiac extracellular fluid compartments (see
“Methods”). The predicted tissue concentration of Ang II
would be 30% to 35% of the arterial concentration. This
discrepancy suggests that extracellular Ang II was rapidly
degraded in the short period (maximally 45 seconds) between
the moment the Ang II infusion had been stopped and the
moment the tissue was transferred into liquid nitrogen.
During perfusion with Ang II in the presence of the
AT1-receptor antagonist losartan (n55), the steady-state Ang
II levels in CE and IST were not significantly different from
the levels during Ang II perfusion in the control situation (Fig
2). Ang II, which was above the detection limit in all cardiac
tissue samples in the control Ang II perfusion experiments,
could not be detected in the tissue samples in the Ang
II/losartan perfusion experiments. This is likely to be due to
blockade of the AT1-receptor–mediated cellular uptake of
extracellular Ang II.
Localization of Arterially Delivered Ang I and
Locally Generated Ang II During Perfusion
With Ang I
During perfusion with Ang I (n55), the steady-state Ang I
level in CE was 48% of the arterial level (Fig 3). Thus 52%
of arterially delivered Ang I was removed by the heart during
a single passage of perfusate. Part of the Ang I removal was
caused by conversion to Ang II (Fig 4).
The steady-state Ang II level in IST was higher than in CE,
whereas the steady-state Ang I level in IST was lower than in
CE. This, together with the finding that during perfusion with
Ang II the Ang II level in IST was also lower than in CE (see
above), indicates that part of the Ang II present in IST during
Ang I perfusion was not derived from Ang II in the perfusate.
The cardiac tissue level of Ang I (per gram of tissue),
shortly after the Ang I perfusion had been switched off, was
'5% of the arterial level (per milliliter of perfusate) (Fig 3).
This is lower than predicted on the basis of the presence of
Ang I in the cardiac extracellular fluid compartments (see
“Methods”). The predicted tissue concentration of Ang I
would be 22% of the arterial concentration. This discrepancy
suggests that extracellular Ang I, like extracellular Ang II,
was rapidly degraded in the short period between the moment
the Ang I infusion had been stopped and the moment the
tissue was transferred into liquid nitrogen.
During perfusion with Ang I in the presence of the
AT1-receptor antagonist losartan (n55), the steady-state Ang
I and II levels in CE and IST were not significantly different
from those during Ang I perfusion in the control situation
(Fig 3 and Fig 4). Ang II, which was above the detection limit
in all cardiac tissue samples in the control Ang I perfusion
experiments, could not be detected in the tissue samples in the
Ang I/losartan perfusion experiments, which is probably due
to blockade of the AT1-receptor–mediated cellular uptake of
extracellular Ang II.
Localization of Locally Generated Ang I and II
During Combined Renin/Angiotensinogen
Perfusion
Results of the combined renin/angiotensinogen perfusions are
shown in Fig 5 and Fig 6. During combined renin/angioten-
Figure 3. Steady-state Ang I concentration in CE and IST dur-
ing perfusion with Ang I for 15 minutes and the Ang I concentra-
tion in cardiac tissue shortly after the perfusion. Perfusions were
carried out in the absence (n55) or presence (n55) of losartan
(1026 mol/L). The mean of the levels of the 7- to 10-minute and
11- to 14-minute perfusion periods was taken as the steady-
state concentration. Data (mean6SD) are presented as a per-
centage of the arterial Ang I concentration. Ang I in IST was
lower than in CE (P,.02) and higher than in cardiac tissue
(P,.02) both with and without losartan.
Figure 4. Steady-state Ang II concentration in CE and IST dur-
ing perfusion with Ang I for 15 minutes and the Ang II concen-
tration in cardiac tissue shortly after the perfusion. Perfusions
were carried out in the absence (n55) or presence (n55) of lo-
sartan (1026 mol/L). The mean of the levels of the 7- to
10-minute and 11- to 14-minute perfusion periods was taken as
the steady-state concentration. Data (mean6SD) are presented
as a percentage of the arterial Ang I concentration. Ang II in IST
was higher than in CE (P,.05) and cardiac tissue (P,.05) both
with and without losartan. n.d. indicates not detectable.
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sinogen perfusion in the absence of losartan (n53), the Ang
I levels in IST in the 31- to 40-minute and 46- to 55-minute
perfusion periods were 4.2 (1.5 to 8.2) and 3.2 (0.9 to 6.5)
times higher than in CE, respectively (mean and range). The
Ang II levels in IST in these perfusion periods were 4.8 (2.7
to 6.8) and 3.8 (2.2 to 5.7) times the levels in CE.
The cardiac tissue level of Ang I, 18.2 (11.4 to 22.8)
fmol/g, shortly after the combined renin/angiotensinogen
perfusion had been switched off, was close to the level
predicted on the basis of the presence of Ang I in the cardiac
extracellular fluid compartments (see “Methods”), '20
fmol/g.
The cardiac tissue level of Ang II, 4.8 (2.8 to 6.4) fmol/g,
was higher than the level predicted on the basis of the
presence of Ang II in the cardiac extracellular fluid compart-
ments, '1.5 fmol/g. This suggests that the presence of the
locally formed Ang II was not limited to the intravascular and
interstitial fluid.
During combined renin/angiotensinogen perfusion in the
presence of the AT1-receptor antagonist losartan (n53), the
Ang I and II levels measured in CE, IST, and cardiac tissue
were similar to the levels measured in the control experiments
without losartan. Thus blockade of the AT1-receptor–medi-
ated uptake of extracellular Ang II in these experiments did
not decrease tissue Ang II to an undetectably low level as it
did in the Ang I and II perfusion experiments.
Discussion
In a previous series of experiments we studied the production
of Ang I by the modified rat Langendorff heart, in which the
ISF transudate could be collected separately from the CE.7
Our present study uses the same isolated heart model and
focuses on the production of Ang II.
As expected, part of the Ang I present in the perfusate
during the combined renin/angiotensinogen perfusions and
formed by the reaction of arterially delivered renin with
arterially delivered angiotensinogen was converted to Ang II
and ejected by the CE. Ang I to II conversion by the coronary
vascular bed has been reported by others.16,17 More interesting
is our finding that during these combined renin/angioten-
sinogen perfusions, the concentration of Ang II in the IST
was several times higher than in the CE, whereas during
perfusions with Ang II, the Ang II concentration in the IST
was lower than in the CE. These results indicate that a
substantial part of Ang II in the ISF was not derived from the
Ang II that was present in the perfusate.
At the time we finished this study, a report was published
by Dell’Italia et al18 on measurements of Ang II in the ISF
space of the dog heart by using microdialysis probes. The
Ang II level in the ISF was higher than in blood plasma and
did not change after systemic infusion of Ang I. These results
indicate compartmentalization of Ang II in the heart between
the interstitial and intravascular fluid compartments. Our
results are in agreement with this conclusion and suggest that
Ang II in the ISF is formed outside the intravascular fluid
compartment.
In the combined renin/angiotensinogen perfusion experi-
ments, the Ang II level we measured in cardiac tissue
(expressed per gram of tissue) was higher than in CE
(expressed per milliliter of fluid). It was in fact as high as in
the IST. This is an indication that the locally produced Ang II
is not restricted to the extracellular fluid and that a large part
Figure 5. Steady-state Ang I concentration in
CE and IST during combined renin/angioten-
sinogen perfusion for 60 minutes and the Ang I
concentration in cardiac tissue shortly after the
perfusion. Perfusions were carried out in the
absence (n53) or presence (n53) of losartan
(1026 mol/L). Data are presented as mean and
half range.
Figure 6. Steady-state Ang II concentration in
CE and IST during combined renin/angiotensino-
gen perfusion for 60 minutes and the Ang II con-
centration in cardiac tissue shortly after the per-
fusion. Perfusions were carried out in the
absence (n53) or presence (n53) of losartan
(1026 mol/L). Data are presented as mean and
half range.
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of this Ang II might be located in the cells, because the
intravascular and interstitial fluid compartments comprise
'38% and 23% of tissue weight, respectively.7 Cellular
binding and uptake through AT1-type Ang II receptors is
known to occur.8–11 125I-Ang II infused into the left cardiac
ventricle of intact pigs is accumulated in cardiac tissue by an
AT1-receptor–dependent process, and the kinetics of Ang II
accumulation and disappearance are compatible with recep-
tor-mediated endocytosis.12
AT1-receptor–mediated binding of Ang II to cardiac cells is
also indicated by our results obtained during the Ang I or II
perfusions, which showed that the cardiac tissue concentra-
tion of Ang II during these perfusions fell to an undetectably
low level when the specific AT1-receptor antagonist losartan
was added to the perfusion fluid. Losartan, however, had no
significant effect on the cardiac tissue concentration of
locally formed Ang II during the combined renin/angioten-
sinogen perfusions. This is in accordance with observations in
rats, which showed an increase and not a decrease in cardiac
tissue Ang II after 8 days of treatment of the animals with
losartan, an increase that is likely to be related to the
stimulated renin release from the kidney after this drug.19 The
apparent discrepancy with respect to the observed effects of
losartan, between the results of the Ang I and II perfusions on
the one hand and the combined renin/angiotensinogen perfu-
sion on the other hand, raises the possibility that during the
combined renin/angiotensinogen perfusion, local Ang II pro-
duction in the heart is taking place in a compartment that is
not reached by losartan, that is, within the cells.
The finding that the measured levels of Ang II in cardiac
tissue in the Ang I and II perfusion experiments were lower
than calculated on the basis of their presence in the extracel-
lular fluid may be explained as follows. Most of the extra-
cellular fluid in the Langendorff heart preparation is localized
in the intravascular compartment, that is, the coronary vas-
cular bed and the right ventricle.7 The half-life of Ang I and
II is '1 minute in the ISF compartment.7 In the intravascular
compartment it is even shorter, '0.1 to 0.2 minute. It is
therefore possible that the short period between the moment
the perfusions had been stopped and the tissue had been
transferred into liquid nitrogen was long enough for the
endothelial peptidases to cause substantial breakdown of
intravascular Ang I and II.
In the combined renin/angiotensinogen perfusion experi-
ments these losses of extracellular Ang II might have been
overcome, at least partly, by ongoing formation of this
peptide during the time that elapsed until the tissue was
frozen. The tissue levels of Ang II we measured in these
combined renin/angiotensinogen perfusion experiments are
therefore probably more close to the true levels at the time of
perfusion than the tissue levels we measured in the Ang I and
II perfusion experiments. Moreover, the Ang II concentration
in the extracellular fluid was several orders of magnitude
higher during the Ang I and II perfusions than during
combined renin/angiotensinogen perfusion. Because of these
higher levels of extracellular Ang II a smaller proportion of it
will be bound to the cardiac cell AT1-receptors and taken up
in the cells, where it is protected against the rapid degradation
to which extracellular Ang II is exposed.11,12,20 Finally, if it is
true that Ang II is produced within the cells during combined
renin/angiotensinogen perfusion, this intracellular Ang II will
similarly be protected against this rapid degradation.
The results of the renin/angiotensinogen perfusion experi-
ments indicate that in contrast with Ang II, most of the locally
produced Ang I in the heart is restricted to the cardiac
extracellular fluid compartments. Likely sites of cardiac Ang
I production are the ISF and a site closer to the blood
compartment, possibly vascular surface-bound renin (Fig 7).7
The question of where in the tissue the Ang II is formed is
incompletely answered by the present study. Part of it is
formed at the vascular endothelial and endocardial surfac-
es.16,21–23 Our observations in the present study on the effects
of blockade of AT1-receptor–mediated uptake of Ang II,
which did not show a change in the tissue level of locally
produced Ang II as opposed to a decrease in the tissue level
of arterially administered Ang II, raise the interesting possi-
bility of intracellular Ang II formation (Fig 7). There is
experimental evidence that neonatal rat cardiac myocytes are
capable of binding and internalizing renin and prorenin
through a mannose 6-phosphate receptor and that prorenin is
activated in the cells.24 Internalized Ang II has a long
half-life, and there is growing evidence that intracellular Ang
II can serve important functions.25–27 AT1-receptor–mediated
uptake of Ang II and the evidence that the formation and
degradation of Ang I and II in cardiac tissue are highly
compartmentalized has implications for the effects of drugs
Figure 7. Proposed scheme of Ang I
and II production in the heart: Intravas-
cular and interstitial fluid compartments
as well as blood vessel wall and cardiac
cells (endothelial cells, myocytes, fibro-
blasts, macrophages) are depicted. Cir-
culating renin and angiotensinogen (Aog)
both enter the interstitial fluid compart-
ment. Renin may also bind to the vascu-
lar wall and cardiac cells.7,24 ACE is
present on endothelial cells and possibly
also on cardiac cells. Ang I and II are
metabolized by peptidases while passing
through the vascular wall. Ang I and II in
the interstitial fluid are mainly generated
outside the vascular fluid compartment.
Tissue Ang I and II generation may occur not only in the interstitial fluid or on the cell surface but also within cells, for instance after
renin uptake by the cells.24 Binding of Ang II to the AT1-receptor is followed by internalization of the AT1-receptor–Ang II complex.
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that interfere with Ang II receptor binding (AT1-receptor
antagonists) or reduce the production of Ang II (renin
inhibitors, ACE inhibitors). These drugs may have different
effects on the Ang II levels in different cardiac tissue
compartments.
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